Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cells()

With the advent of enzyme replacement therapy (ERT) with alglucosidase alfa (rhGAA, Myozyme®) for Pompe disease, the clinical course of the disease has changed. We have previously described the poor outcome in cross reactive immunologic material (CRIM)-negative and high-titer CRIM-positive (HTCP) pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Banugaria, Suhrad G., Patel, Trusha T., Mackey, Joanne, Das, Stuti, Amalfitano, Andrea, Rosenberg, Amy S., Charrow, Joel, Chen, Y.-T., Kishnani, Priya S.
Format: Artigo
Language:Inglês
Published: 2012
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3711263/
https://ncbi.nlm.nih.gov/pubmed/22365055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymgme.2012.01.019
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items